Novel therapeutic strategy for human epidermal growth factor receptor 2-positive gastric cancer

Nobuhiko Kanaya, Shinji Kuroda, Tetsushi Kubota, Toshiaki Morihiro, Satoru Kikuchi, Masahiko Nishizaki, Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara

Research output: Contribution to journalReview article

Abstract

Trastuzumab (Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2 (HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanopartides, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanopartides and demonstrate their efficacy for the treatment of HER2-positive, Tmab-resistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanopartides have the potential to be a novel HER2-targeted therapeutic agent.

Original languageEnglish
Pages (from-to)883-885
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Volume44
Issue number10
Publication statusPublished - Oct 1 2017

Fingerprint

Stomach Neoplasms
Gold
Therapeutics
Breast Neoplasms
Peptide Nucleic Acids
Antibodies, Monoclonal, Humanized
Nanotechnology
human ERBB2 protein
Trastuzumab
Stomach
Cell Line
Antibodies
Pharmaceutical Preparations
Neoplasms

Keywords

  • Gastric cancer
  • Human epidermal growth factor receptor 2 (HER2)
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{2ae25d35775249af964c25e54640f909,
title = "Novel therapeutic strategy for human epidermal growth factor receptor 2-positive gastric cancer",
abstract = "Trastuzumab (Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2 (HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanopartides, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanopartides and demonstrate their efficacy for the treatment of HER2-positive, Tmab-resistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanopartides have the potential to be a novel HER2-targeted therapeutic agent.",
keywords = "Gastric cancer, Human epidermal growth factor receptor 2 (HER2), Trastuzumab",
author = "Nobuhiko Kanaya and Shinji Kuroda and Tetsushi Kubota and Toshiaki Morihiro and Satoru Kikuchi and Masahiko Nishizaki and Hiroshi Tazawa and Shunsuke Kagawa and Toshiyoshi Fujiwara",
year = "2017",
month = "10",
day = "1",
language = "English",
volume = "44",
pages = "883--885",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "10",

}

TY - JOUR

T1 - Novel therapeutic strategy for human epidermal growth factor receptor 2-positive gastric cancer

AU - Kanaya, Nobuhiko

AU - Kuroda, Shinji

AU - Kubota, Tetsushi

AU - Morihiro, Toshiaki

AU - Kikuchi, Satoru

AU - Nishizaki, Masahiko

AU - Tazawa, Hiroshi

AU - Kagawa, Shunsuke

AU - Fujiwara, Toshiyoshi

PY - 2017/10/1

Y1 - 2017/10/1

N2 - Trastuzumab (Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2 (HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanopartides, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanopartides and demonstrate their efficacy for the treatment of HER2-positive, Tmab-resistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanopartides have the potential to be a novel HER2-targeted therapeutic agent.

AB - Trastuzumab (Tmab), a humanized monoclonal antibody that selectively targets human epidermal growth factor receptor 2 (HER2), is currently used in the clinical setting for the treatment of both breast and gastric cancer. While Tmab has shown improvements in patient prognoses, acquired resistance to this agent remains an issue. While some novel HER2-targeted agents have been approved for clinical use in breast cancer, no such agent has shown treatment efficacy for gastric malignancies with Tmab-resistance. Nanotechnology, which has progressed rapidly, has been applied to medical fields in recent years. Gold nanopartides, which are characterized by their in vivo stability and ease of surface modification, have been reported to show efficacy as the carriers of therapeutic agents, such as drugs, antibodies, peptides, and nucleic acids. In this work, we developed Tmab-conjugated gold nanopartides and demonstrate their efficacy for the treatment of HER2-positive, Tmab-resistant gastric cancer cell lines. Our findings demonstrate that Tmab-conjugated gold nanopartides have the potential to be a novel HER2-targeted therapeutic agent.

KW - Gastric cancer

KW - Human epidermal growth factor receptor 2 (HER2)

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85040528106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040528106&partnerID=8YFLogxK

M3 - Review article

C2 - 29066684

AN - SCOPUS:85040528106

VL - 44

SP - 883

EP - 885

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 10

ER -